Register for free to
view the full innovation profile.
Novel anti fungal mechanism of action; low animal and plant toxicities and cytotoxicities; scalable production at kg levels;
About
New Synthestic Antifungal Agents - K20 and Related Compounds Technical Summary Dr. Tom Chang and Dr. Jon Takemoto of Utah State University’s Chemistry/Biochemistry and Biology departments have developed a kanamycin derivative (K20) antifungal compound that inhibits candida, cryptococcus and other fungal species including azole-resistant strains. K20 is a derivative of the aminoglycoside antibiotic kanamycin. K20 is distinguished from the parent molecule kanamycin A by the presence of functional groups terminating in either an alkyl or phenyl group in the 6 position of ring III. Structurally related compounds are also developed. A preferred embodiment of K20 is the treatment of fungal infections of hosts wherein antifungal azole resistance is problematic. Commercial Applications Pharmaceutical companies Medical and chemical supply companies Agrichemical companies Competitive Advantages K20 derived from available parent molecule, kanamycin A Novel antifungal mechanism of action Low animal and plant toxicities and cytotoxicities Scalable production at kg levels Shows considerable inhibitory activity against several animal and plant fungal pathogens May be administered through spraying, direct injection, topical application, oral administration, or by inclusion to the water supply